Skip to main content
. Author manuscript; available in PMC: 2018 Aug 1.
Published in final edited form as: Cancer Immunol Res. 2017 Jul 3;5(8):685–694. doi: 10.1158/2326-6066.CIR-16-0330

Figure 5. Analysis of tumors treated with PBS, SS1P, PBS and anti-CTLA-4 or SS1P and anti-CTLA-4.

Figure 5

(A) Sections of tumors stained with H and E. Areas outlined in green are necrotic, areas out-lined in yellow show micro-abscesses, and areas with viable tumor cells are outlined in red. The area outlined in blue in the tumor treated with SS1P and anti-CTLA-4 is a collar containing inflammatory cells. (B) Sections of tumors stained with anti-CD8 at low magnification (1X). (C) Sections of tumors stained with anti-CD8 at high magnification (5X). Tumors from the PBS, SS1P and PBS with anti-CTLA-4 groups were harvested when the tumors reached about 300 mm3 in size. Tumors from the combination treated group were harvested when the tumor volume was reduced by 20–60% from the maximum (8 mice). (D) Number of CD8+ T cells present in the tumor mass. (E) Number of CD8+ T cells in the collar surrounding the tumor.